<DOC>
	<DOCNO>NCT01037348</DOCNO>
	<brief_summary>This study design provide efficacy safety data patient choroidal neovascularisation ( CNV ) secondary myopia use individualize as-needed ( PRN ) dose schedule . Eligible patient provide write agreement take part study receive intravitreal ( study eye ) injection ranibizumab 0.5mg . Following eye examination test monthly clinic visit , study doctor repeat injection monthly basis require additional 11 month , accordance specify retreatment criterion . Patients study approximately 12 month visit hospital clinic 14 time period . The main assessment include visual acuity test , eye examination , optical coherence tomography ( OCT ) assess retinal thickness , fundus photography fluorescein angiography ( FA ) , measurement intraocular pressure , blood pressure pulse measurement completion health-related questionnaire ' .</brief_summary>
	<brief_title>Ranibizumab Treatment Choroidal Neovascularisation ( CNV ) Secondary Pathological Myopia ( PM ) : Individualized Regimen</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female outpatient race , age 18 year old Diagnosis active primary recurrent subfoveal juxtafoveal CNV secondary PM Diagnosis high myopia least 6 dioptre study eye spherical equivalent . For subject undergone prior refractive cataract surgery study eye , preoperative refractive error study eye must least 6 dioptre Patients BCVA score 78 24 letter study eye use Early Treatment Diabetic Retinopathy Study ( ETDRS ) like grade chart ( approximately 6/9 6/96 Snellen equivalent ) Patients must give fully inform consent willing able comply study procedure History surgical intervention study eye within two month precede screen Previous macular laser photocoagulation , treatment intravitreal steroid , verteporfin photodynamic therapy ( Visudyne® ) antiVEGF agent ranibizumab , bevacizumab pegaptanib sodium ( Macugen® ) study eye Previous treatment intravenously administer bevacizumab ( Avastin® ) Prior treatment study eye externalbeam radiation therapy , vitrectomy , transpupillary thermotherapy History hypersensitivity study drug drug similar chemical class History allergic reaction fluorescein Concurrent use systemic antiVEGF agent Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Choroidal Neovascularisation</keyword>
	<keyword>Pathological Myopia</keyword>
</DOC>